Childhood Primary Central Nervous System Vascultis Treatment Protocols

Similar documents
Childhood Primary Central Nervous System Vascultis Treatment Protocols

RATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with

Treatment of Susac s Syndrome (SS)

MEDICATIONS: THE GOOD, THE BAD, THE UGLY

EULAR/ERA-EDTA recommendations for the management of ANCAassociated

Understanding Myositis Medications

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) Case presentations and topic discussion The Rheumatology Unit UMMC experience

Answers to Self Assessment Questions

UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS

EudraCT number: Page 8 of 42

Lupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017

Cyclophosphamide cerebral vasculitis dosing

Lupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia

TREATMENT OF ANCA-ASSOCIATED VASCULITIS

Acute and chronic treatments

ANCA+ VASCULITIDES CYCAZAREM,

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication

Case study 1: A Bayesian clinical trial in children with polyarteritis nodosa (PAN)

Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ

LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE

APPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up

Everyday Vasculitis (or what questions do we get asked most!) Lucy Smyth Renal Consultant

Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS

Recent Advances in Neurology Difficult Cases

9/30/ DISCLOSURES. + First: Why immunosuppress? Transplant Immunosuppression and Prophylaxis

EudraCT number: Page 9 of 46

Adult Primary Central Nervous System Vasculitis Treatment and Course

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

Technology appraisal guidance Published: 26 March 2014 nice.org.uk/guidance/ta308

Treatment with steroids and immunosuppressants

Management of uveitis

Risk of Pneumocystosis among Patients Receiving Immunosuppressive Therapies: a population based analysis in the United States

Situaciones estresantes en el lupus

Adalimumab in Noninfectious Uveitis of Idiopathic Etiology Efficacy Across Different Anatomical Locations the VISUAL I and VISUAL II Trials

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma

KDIGO GN Guideline update Evidence summary. Steroid-sensitive nephrotic syndrome. Corticosteroid therapy for nephrotic syndrome in children

TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014

Clinical Commissioning Policy Proposition: Tocilizumab for Takayasu arteritis (adults)

BK Virus (BKV) Management Guideline: July 2017

Kawasaki Disease: What you need to know from the 2017 Guidelines

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

Cases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center

PAEDIATRIC VASCULITIS

Recent advances in management of Pulmonary Vasculitis. Dr Nita MB

LONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS. Hong Kan 7/12/2016

CENTRAL NERVOUS SYSTEM VASCULITIS

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018

Sarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material

Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study

Moderately to severely active ulcerative colitis

Additional file 2: Details of cohort studies and randomised trials

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital

Serologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I

New Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis

APPLICATION FOR SPECIAL AUTHORITY. Subsidy for Infliximab

IRACON Management of Lupus Nephritis: Old is gold, New is Trendy

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

Small Vessel Vasculitis

CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)

Rheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University

10/27/2013. Funding from the Autoimmune Encephalitis Alliance. Heather Van Mater, MD MS October 27, 2013

Evidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes

Scottish Medicines Consortium

Scleritis LEN V KOH OD

TAKAYASU S ARTERITIS. Second-stage symptoms include:

Vasculitides in Surgical Neuropathology Practice

Cerebral Toxoplasmosis in HIV-Infected Patients. Ahmed Saad,MD,FACP

Nephrotic Syndrome NS

4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed

Novel Therapies in Autoimmune Hepatitis

Rheumatology Suggested Reading List. Compiled by Rebecca Sharim MD. Updated: 4/6/17

Autoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015

SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS

Clinical Guidance. Kawasaki disease. Summary This guideline includes therapy and follow up including investigations (echocardiography, MRI).

Immunizing the Immunocompromised. Leilani T. Sanchez, MD, DPPS, DPIDSP Crowne Plaza Galleria Manila, 21 February 2013

PICU CARD SURG Post Operative Cardiac Transplant Age LESS than 6 months (Page 1 of 5)

Management of Pyoderma Gangrenosum Mentoring in IBD XVII

The CARI Guidelines Caring for Australasians with Renal Impairment. Idiopathic membranous nephropathy: use of other therapies GUIDELINES

Childhood primary angiitis of the central nervous system: poor neurologic outcome despite treatment

A COST EFFECTIVENESS ANALYSIS OF WEEKLY COMPLETE BLOOD COUNT MONITORING FOR LEUKOPENIA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) ON

MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS

Switching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome

Pharmacy Management Drug Policy

Case Report Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies

Treatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)

BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~

Clinical Policy: Ibrutinib (Imbruvica) Reference Number: ERX.SPA.08 Effective Date:

CHECK LIST FORM-SCREENING

Cyclophosphamide for large-vessel vasculitis: assessment of response by PET/CT

Uveitis unplugged: systemic therapy

Wegener s Granulomatosis

CIMZIA (certolizumab pegol)

CHECK LIST FORM-SCREENING

Special Authorization Drug Products with

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions

Neuromyelitis Optica Is there a Standard of Care? EMA Workshop on NMO London, October 10, 2014

Transcription:

Childhood Primary Central Nervous System Vascultis Treatment Protocols Last updated November 2015

Non-progressive large vessel primary CNS vasculitis* Adjunctive immunosuppression f 3 months IV Methylprednisolone 30/kg (max 1g) x days (3 to 5) Month 1 2 /kg (max 60g) x 3 months tapering monthly e.g. 60-50-40 Month 2 Month 3 Repeat Vascular Imaging Progression: new vascular stenosis new territies involved Progression on imaging Rapid taper Weekly taper e.g. 30-25-20-15-10-5-stop Begin progressive cpacns protocol Calcium (1000 /day PO) Optional: Acyclovir (80 /kg/day PO divided QID, consider renal adjustment) x days (5 to 14, if indicated) * Includes entities of: Angiography-positive, non-progressive primary CNS vasculitis (NPcPACNS), Transient cerebral arteriopathy (TCA), Focal cerebral arteriopathy (FCA), and Post-varicella angiopathy (PVA)

Progressive primary large vessel CNS vasculitis* Phase 1: Induction Therapy (0-6 months) IV Methylprednisolone pulses 30/kg (max 1g) x days (3-7) 2 /kg (max 60g) tapering monthly** Cyclophosphamide (500-750 /m 2 monthly x 7 doses) Trimethoprim/sulfamethoxazole (PJP prophylaxis dosing) Calcium (1000 /day PO) *Angiography-positive, progressive primary CNS vasculitis (PcPACNS) ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 1

Progressive primary large vessel CNS vasculitis* Phase 2: Maintenance Therapy (7-18 months) Tapering monthly** Choose: End of taper date Mycophenolate mofetil (800-1200 /m 2 divided BID) : Mycophenolic acid (500-800 /m 2 divided BID) : Azathioprine (2-3 /kg, max 150, PO daily) : Calcium (1000 /day PO) *Angiography-positive, progressive primary CNS vasculitis (PcPACNS) ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 2

Primary small vessel CNS vasculitis* Phase 1: Induction Therapy (0-6 months) IV Methylprednisolone pulses 30/kg (max 1g) x days (3-7) 2 /kg (max 60g) tapering monthly** Cyclophosphamide (500-750 /m 2 monthly x 7 doses) Trimethoprim/sulfamethoxazole (prophylaxis dosing) Calcium (1000 /day PO) *Angiography-negative, brain-biopsy positive small vessel primary CNS vasculitis (SVcPACNS) ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 1

Primary small vessel CNS vasculitis* Phase 2: Maintenance Therapy (6-18 months) Tapering monthly** Choose: Mycophenolate mofetil (800-1200 /m 2 divided BID) : Mycophenolic acid (500-800 /m 2 divided BID) : Azathioprine (2-3 /kg, max 150, PO daily) : Calcium (1000 /day PO) *Angiography-negative, small vessel primary CNS vasculitis (SVcPACNS) ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 2

Refracty primary CNS vasculitis* Phase 1: Induction 0-6 months 2 /kg (max 60g) tapering biweekly** Infliximab (5-7.5 /kg IV, at diagnosis and after 2 weeks, then monthly) IVIG (2g/kg max 70g, monthly) Methotrexate (10-15 /m 2 PO/subcutaneously weekly) : Calcium (1000 /day PO) Folic Acid (1 /day PO) * Failure to respond to induction therapy ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 1

Refracty primary CNS vasculitis* Phase 2: Maintenance (7-12 months) Infliximab (5-7.5 /kg IV monthly) Optional: IVIG (2g/kg max 70g, monthly) ) Methotrexate (10-15 /m 2 PO/subcutaneously weekly) : Calcium (1000 /day PO) Folic Acid (1 /day PO) * Failure to respond to induction therapy ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 2

Disease activity flare of primary CNS vasculitis* Treat f 6 months Min flare 2 /kg (max 60g) tapering biweekly** IVIG (2g/kg max 70g, monthly) Mycophenolate mofetil (800-1200 /m 2 divided BID) : Mycophenolic acid (500-800 /m 2 divided BID) : Calcium (1000 /day PO) Maj flare Choose as per clinical presentation: Repeat Phase 1: Induction Therapy protocol Proceed to Refracty Primary CNS Vasculitis Therapy protocol * Defined as recurrence of symptoms relative to baseline functional status ** Example prednisone taper schedule: 60 /day, 50, 40, 30, 25, 20, 17.5, 15, 12.5, 10, 7.5, 5, 2.5, stop 1